Skip to content
Screener

Evolus EOLS Business Segments — R&D

Similar metrics at other companies

Immunovant, Inc. logo
IMVTReportable Segment — R&D
$29.22M-6.2%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — R&D
$16M-27.3%
Neurocrine Biosciences logo
NBIXReportable Segment — R&D
$296.2M+12.5%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — R&D
$57.09M+21.8%
Zevra Therapeutics, Inc. logo
ZVRAReportable Segment — R&D
$2.28M-2.5%
Zymeworks logo
ZYMEReportable Segment — R&D
$27.44M-20.4%

Other financials

Income statement

See full
Revenue$84.1M+21.2%
Gross profit$57.2M+26.2%
Operating income-$4.5M+55.5%
Net income-$8.1M+53.0%
EPS (diluted)-$0.12+55.6%

Balance sheet

See full
Cash & equivalents$45.2M-26.8%
Total debt$164.8M+12.3%
Total equity-$30.9M-65.7%
Total assets$248.0M+8.4%

Cash flow

See full
Operating cash flow-$3.6M+85.5%
CapEx$50.0K-92.7%
Free cash flow-$3.6M+85.7%

Valuation

See full
Market cap$500M+31.0%
Enterprise value$619.64M+32.8%
P/S1.6×+0.2×

Profitability

See full
Gross margin66.7%-0.4pp
Operating margin-13.7%-1.9pp
Net margin-10.9%-3.7pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×—
Current ratio1.7×-0.6×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The source filing: Evolus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:56 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053468
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of goods sold26,90424,06751,14445,934
Gross profit57,18045,320106,07791,975
Less:
Research and development1,8921,8374,1324,049
Selling, general and administrative57,05256,675109,033113,315
Depreciation and amortization1,5299323,0671,756
Interest income(296)(479)(581)(1,189)
Interest expense4,1727,2078,14711,622

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Evolus's business segments — R&D?
Evolus (EOLS) reported business segments — R&D of $1.89M in Q2 2026.
How has Evolus's business segments — R&D changed year-over-year?
Evolus's business segments — R&D increased by 3.0% year-over-year, from $1.84M to $1.89M.
What is the long-term trend for Evolus's business segments — R&D?
Over 3 years (2022 to 2025), Evolus's business segments — R&D has grown at a 28.9% compound annual growth rate (CAGR), from $4.47M to $9.58M.
What does business segments — R&D mean?
Captures the expenses incurred by the segment for scientific research, clinical trials, and the development of new aesthetic product formulations. It reflects the company's commitment to innovation and long-term pipeline growth within the self-pay aesthetic market.

Ask your AI about Evolus's business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude